Early and late term management in caustic ingestion in children: a 16-year experience.
Accidental corrosive ingestion is one of the common problems causing serious esophageal strictures in children. The acute phase treatment has a great effect on stricture development. In this study we aim to present our experience in the management of caustic ingestion, particularly during the acute phase. From January 1990 to January 2005, 296 children were admitted to our clinic with caustic ingestion. Ninety-one patients who received dilatation treatment due to esophageal strictures constituted the present study group. Forty-three of them were admitted to our centre immediately after caustic ingestion (Group A) whereas 48 of them received some kind of treatment in other hospitals and were referred us with the diagnosis of stricture 6 to 12 weeks after ingestion (Group B). In the acute phase, the patients were given nothing orally until esophagoscopy was performed in the first 24-48 hours. The patients with grades 2b and 3 lesions underwent a week of esophageal rest by using a nasogastric tube. IV fluids and broad-spectrum antibiotics with a single-dose steroid were given. IV ranitidine was also added to the medical treatment. If there were stricture formations on barium meal after 3 weeks, these patients underwent esophageal dilatation programmes. The response rates to dilatation treatment were higher in group A. In addition, increased perforation rates were observed in group B. Sixty per cent of patients in group A but none of the patients in group B have recovered in the first year. In conclusion, after caustic ingestion, esophageal rest combined with supporting treatment seems to provide a good success rate with respect to prevention of stricture development and other troublesome complications.
Gün
F
F
I.U. Istanbul School of Medicine, Department of Pediatric Surgery, Istanbul, Turkey.
Abbasoğlu
L
L
Celik
A
A
Salman
E T
ET
D000059:Accidents; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002057:Burns, Chemical / Q000209:etiology* / Q000628:therapy; D002404:Catheterization; D002424:Caustics / Q000009:adverse effects*; D002675:Child, Preschool; D004940:Esophageal Stenosis / Q000139:chemically induced / Q000628:therapy; D004945:Esophagoscopy; D004947:Esophagus / Q000293:injuries*; D005260:Female; D005440:Fluid Therapy; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use; D020127:Recovery of Function; D013997:Time Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D002424:Caustics; D006635:Histamine H2 Antagonists; D011899:Ranitidine